GlassScriptPhysician profile
Lee Grafton
NPI 1700881141
$19,376.53
in general payments reported to CMS, 2019-2025
43 companies · $3,915 in 2025
The $3,915 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,999 · 2020: $2,025 · 2021: $2,261 · 2022: $2,616 · 2023: $3,394 · 2024: $3,166 · 2025: $3,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,824 · Education: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,824.08 |
| Education | $650.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,381.85 | 2019-2025 | |
| Janssen Biotech, INC. | $1,877.46 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $1,564.28 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,389.89 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $1,179.70 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $1,033.93 | 2019-2025 | |
| Ucb, INC. | $1,008.34 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $1,003.23 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $886.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $678.89 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $545.62 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $373.68 | 2019-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $361.97 | 2019-2023 | |
| Hill Dermaceuticals, INC. | $347.33 | 2023-2024 | Tolak |
| Medimetriks Pharmaceuticals, INC. | $346.53 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $336.69 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $256.35 | 2023-2024 | Vtama |
| Incyte Corporation | $188.22 | 2023-2025 | Opzelura |
| Organon LLC | $177.27 | 2025 | Vtama |
| Biofrontera INC. | $175.43 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organogenesis INC. | $150.96 | 2024-2025 | Affinity, Via Matrix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $131.10 | 2019-2023 | Arazlo, Targretin, Siliq |
| Genentech USA, INC. | $104.63 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $95.69 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.84 | 2023-2025 | Spevigo, Cyltezo |
| Celgene Corporation | $79.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Almirall LLC | $65.60 | 2022-2025 | Klisyri |
| Galderma Laboratories, L.P. | $62.81 | 2020-2025 | Nemluvio |
| Merz North America, INC. | $60.98 | 2019-2020 | |
| Convatec INC. | $52.25 | 2024-2025 | |
| Allergan, INC. | $42.38 | 2020-2021 | |
| Journey Medical Corporation | $37.73 | 2023-2024 | |
| Pierre Fabre Pharmaceuticals, INC. | $33.96 | 2019-2020 | |
| Epi Health, LLC | $31.08 | 2019 | |
| Mallinckrodt Hospital Products INC. | $27.08 | 2025 | Acthar |
| Sandoz INC. | $22.89 | 2023 | Hyrimoz |
| Strata Skin Sciences, INC. | $21.80 | 2022 | |
| Dermira, INC. | $19.78 | 2020 | |
| Botanix Sb INC | $17.71 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $17.16 | 2020 | |
| Merck Sharp & Dohme LLC | $15.50 | 2019 | |
| Krystal Biotech INC | $13.54 | 2025 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Grafton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.